Doctoral supervisor:Jinglun Xue

       Chief professor of Fudan University, the first person in gene therapy for genetic diseases in China, and a recipient of special allowances from the State Council.

       The various achievements in gene therapy for hemophilia B won the 1996 Ho Leung Ho Lee Award and Tan Jiazhen Life Sciences Outstanding Contribution Award, 1997 Second Prize of National Technological Invention Award, First Prize of State Education Commission Science and Technology Progress Award, First Prize of Shanghai Science and Technology Progress Award and other provincial and ministerial awards. The Ministry was rated as an advanced individual who made important contributions in the work of the national high-tech research and development plan, and was the tutor of 100 excellent doctoral dissertations in the country in 2001. In 2003, he was rated as an excellent doctoral tutor.

        Engaged in medical genetics teaching and research for more than 40 years. Since 1987, under the support of the national "863" plan, he has been committed to gene therapy research, and systematically carried out basic and clinical trials of hemophilia B gene therapy. Obtained the first approval document of "Human Observation of New Biological Products" issued by the Ministry of Health of my country. It was the first clinical trial of gene therapy for hemophilia B in the world, and the clinical gene therapy of 4 patients with hemophilia B was successfully completed. The intended purpose of being safe and effective is the first example of systematic and successful gene therapy for genetic diseases in my country so far;  Recombinant AAV-2/human coagulation factor IX developed with Beijing Benyuan Zhengyang Gene Technology Co., Ltd. in 2003 "Injection" obtained the approval for drug clinical research from the State Drug Administration, bringing the clinical research of hemophilia B gene therapy into a new realm.

       Project 973 since 2004 "Applied Basic Research in Gene Therapy" Sub-project (fixed-point integration, in-situ repair technology and mechanism research) group leader; also undertakes“RepGene therapy by site-directed integration", "RepMediated Application Research of Site-Directed Integration” etc.863 project research, training more than 200 doctoral and master students.

       Published more than 200 research papers including NAR, JMB and other authoritative journals, and published more than 10 monographs in the field of medical genetics .